Treos Bio - About the company
Treos Bio is a series B company based in London (United Kingdom), founded in 2013 by John Hautman. It operates as a Developer of cancer vaccines and companion diagnostics. Treos Bio has raised $22M in funding from Luminous Ventures, with a current valuation of $*****. The company has 702 active competitors, including 189 funded and 150 that have exited. Its top competitors include companies like Guardant Health, Natera and Foundation Medicine.
Company Details
Developer of cancer vaccines and companion diagnostics. Its platform technology uses proprietary algorithms to mine patient genetic profiles and match them to their response to therapeutic vaccines. It has two diagnostic products. The PEPI test is a genetic test that predicts the patient's antigen-specific immune response, which in turn can be used to predict the patient's response to therapeutic cancer vaccines. The PEPI test is approved as an IVD kit in Europe. The other diagnostic test under development is the Melanoma PEPI Test for identifying high-risk melanoma patients. In addition, the company is developing the PolyPEPI vaccine and companion diagnostic family of products for melanoma, breast cancer, and lung cancer. The companion diagnostics will be used for the biomarker-based stratification of patients.
- Website
- www.treosbio.com/
- Email ID
- *****@treosbio.com
- Phone Number
- +1 **********
- Registered Address
- 79 New Cavendish Street, The Harley Building, London, London, England, W1W 6XB
Key Metrics
Founded Year
2013
Location
London, United Kingdom
Stage
Series B
Total Funding
$22M in 2 rounds
Latest Funding Round
Post Money Valuation
$***** as on Jun 10, 2020
Investors
Ranked
46th among 702 active competitors
Annual Revenue
£0 - £1M as on Dec 31, 2023
Employee Count
17 as on Sep 30, 2026
Similar Companies
Legal entities associated with Treos Bio
Treos Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Treos Bio Limited CIN: 10438750 , United Kingdom, Active | Oct 19, 2016 | £0 - £1M (As on Dec 31, 2023) | 12 (As on Dec 31, 2020) |
Sign up to download Treos Bio's company profile
Treos Bio's funding and investors
Treos Bio has raised a total funding of $22M over 2 rounds. Its first funding round was on Feb 13, 2017. Its latest funding round was a Series B round on Mar 31, 2021 for $*****. 2 investors participated in its latest round. Treos Bio has 17 institutional investors and 28 angel investors.
Here is the list of recent funding rounds of Treos Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 31, 2021 | 3733505 | Series B | 1497842 | 5116780 | 6518760 | 2916606 |
Feb 13, 2017 | 1803896 | Series A | 3471169 | 4928460 | 3494163 | 3313578 |
Access funding benchmarks and valuations. Sign up today!View details of Treos Bio's funding rounds and investors
Treos Bio's founders and board of directors
Founder? Claim ProfileThe founders of Treos Bio is John Hautman.
Here are the details of Treos Bio's key team members:
- John Hautman: Co-Founder of Treos Bio. Contact Info: 1 email address
View details of Treos Bio's Founder profiles and Board Members
Treos Bio's employee count trend
Treos Bio has 17 employees as of Sep 26. Here is Treos Bio's employee count trend over the years:
Uncover Treos Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Treos Bio's Competitors and alternates
Top competitors of Treos Bio include Guardant Health, Natera and Foundation Medicine. Here is the list of Top 10 competitors of Treos Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
4th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
5th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
6th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
7th |  ImmunityBio 2014, El Segundo (United States), Public | Developer of peptide-based vaccines for immunotherapy | $169M | 67/100 | |
8th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
9th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
10th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 64/100 | |
46th | Treos Bio 2013, London (United Kingdom), Series B | Developer of cancer vaccines and companion diagnostics | $22M | 51/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Treos Bio's competitors? Click here to see the top ones
Treos Bio's Investments and acquisitions
Treos Bio has made no investments or acquisitions yet.
Reports related to Treos Bio
Here is the latest report on Treos Bio's sector:
News related to Treos Bio
Filter this listMedia has covered Treos Bio for 1 event in last 1 year, It was about company updates.
•
•
TREOS Bio Partners with Charité Berlin and Junshi to Launch Phase II TrialGlobeNewswire•Aug 27, 2025•Charite, Junshi BioPharma, Treos Bio
•
•
•
Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-InhibitorPipelinereview•Jul 08, 2021•Treos Bio, Roche
•
•
•
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide VaccinePipelinereview•Jun 15, 2020•Treos Bio
•
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster PresentationPipelinereview•May 31, 2020•Treos Bio
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Treos Bio
Explore our recently published companies
- ACOUSTIC BOARD - India based, 2014 founded, Unfunded company
- Straight Line CP - Bellevue based, Unfunded company
- Quality Piano Moves - New York City based, Unfunded company
- Linkern - Morocco based, 2018 founded, Unfunded company
- Marie Fe - Vancouver based, 2026 founded, Unfunded company
- Tokyo Lawn Tennis Club - Japan based, 1900 founded, Unfunded company
